Loading...

Onxeo

OTCPK:OXNX.F
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OXNX.F
OTCPK
€51M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. The last earnings update was 159 days ago. More info.


Add to Portfolio Compare Print
OXNX.F Share Price and Events
7 Day Returns
0%
OTCPK:OXNX.F
9.2%
US Biotechs
2.2%
US Market
1 Year Returns
-
OTCPK:OXNX.F
-5.3%
US Biotechs
-8.4%
US Market
OXNX.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Onxeo (OXNX.F) 0% 0% - - -72.6% -
US Biotechs 9.2% 2.8% -6.2% -5.3% -0.4% 16.1%
US Market 2.2% -3.1% -10.3% -8.4% 31.7% 32.6%
1 Year Return vs Industry and Market
  • No trading data on OXNX.F.
  • No trading data on OXNX.F.
Price Volatility
OXNX.F
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Onxeo undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Onxeo. This is due to cash flow or dividend data being unavailable. The share price is $1.16.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Onxeo's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Onxeo's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:OXNX.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-1.11
ENXTPA:ONXEO Share Price ** ENXTPA (2018-10-12) in EUR €1.01
United States of America Biotechs Industry PE Ratio Median Figure of 32 Publicly-Listed Biotechs Companies 25.47x
United States of America Market PE Ratio Median Figure of 3,018 Publicly-Listed Companies 16.54x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Onxeo.

OTCPK:OXNX.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ONXEO Share Price ÷ EPS (both in EUR)

= 1.01 ÷ -1.11

-0.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Onxeo is loss making, we can't compare its value to the US Biotechs industry average.
  • Onxeo is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Onxeo's expected growth come at a high price?
Raw Data
OTCPK:OXNX.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.91x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
93.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.72x
United States of America Market PEG Ratio Median Figure of 2,101 Publicly-Listed Companies 1.2x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Onxeo, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Onxeo's assets?
Raw Data
OTCPK:OXNX.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €0.83
ENXTPA:ONXEO Share Price * ENXTPA (2018-10-12) in EUR €1.01
United States of America Biotechs Industry PB Ratio Median Figure of 398 Publicly-Listed Biotechs Companies 3.16x
United States of America Market PB Ratio Median Figure of 5,086 Publicly-Listed Companies 1.7x
OTCPK:OXNX.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ONXEO Share Price ÷ Book Value per Share (both in EUR)

= 1.01 ÷ 0.83

1.21x

* Primary Listing of Onxeo.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Onxeo is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Onxeo's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Onxeo has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Onxeo expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
93.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Onxeo expected to grow at an attractive rate?
  • Unable to compare Onxeo's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Onxeo's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Onxeo's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:OXNX.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:OXNX.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 93.4%
OTCPK:OXNX.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -53.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 21.3%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:OXNX.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:OXNX.F Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 4 -12 1
2018-12-31 3 -15 1
OTCPK:OXNX.F Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 8 -22 -56
2018-03-31 9 -25 -58
2017-12-31 10 -28 -59
2017-09-30 8 -23 -41
2017-06-30 6 -19 -23
2017-03-31 5 -18 -23
2016-12-31 4 -18 -23
2016-09-30 4 -20 -21
2016-06-30 4 -23 -19
2016-03-31 4 -23 -19
2015-12-31 3 -23 -19
2015-09-30 13 -19 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Onxeo is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Onxeo's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:OXNX.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Onxeo Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:OXNX.F Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31 -0.23 -0.23 -0.23 1.00
2018-12-31 -0.29 -0.29 -0.29 1.00
OTCPK:OXNX.F Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -1.11
2018-03-31 -1.14
2017-12-31 -1.17
2017-09-30 -0.80
2017-06-30 -0.45
2017-03-31 -0.46
2016-12-31 -0.48
2016-09-30 -0.48
2016-06-30 -0.47
2016-03-31 -0.48
2015-12-31 -0.48
2015-09-30 -0.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Onxeo will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Onxeo's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Onxeo has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Onxeo performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Onxeo's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Onxeo does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Onxeo's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Onxeo's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Onxeo's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Onxeo Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:OXNX.F Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 8.24 -56.28 19.29
2018-03-31 8.87 -57.68 22.53
2017-12-31 9.51 -59.07 25.77
2017-09-30 7.71 -41.07 25.67
2017-06-30 5.91 -23.07 25.56
2017-03-31 5.17 -22.87 24.84
2016-12-31 4.42 -22.67 24.11
2016-09-30 4.12 -20.98 23.52
2016-06-30 3.83 -19.29 22.92
2016-03-31 3.65 -19.35 23.00
2015-12-31 3.48 -19.41 23.08
2015-09-30 13.22 -12.75 23.56
2015-06-30 22.96 -6.09 24.05
2015-03-31 22.52 -6.90 22.36
2014-12-31 22.08 -7.70 20.68
2014-09-30 11.68 -14.24 18.64
2014-06-30 1.27 -20.79 16.60
2014-03-31 1.37 -18.06 16.32
2013-12-31 1.47 -15.32 16.03
2013-09-30 2.75 -13.26 15.04
2013-06-30 4.03 -11.20 14.02
2013-03-31 4.03 -11.37 13.39
2012-12-31 4.03 -11.55 12.76
2012-09-30 3.46 -12.63 13.45
2012-06-30 2.89 -13.71 14.14
2012-03-31 3.06 -14.16 15.06

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Onxeo has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Onxeo has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Onxeo improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Onxeo's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Onxeo has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Onxeo's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Onxeo's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Onxeo is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Onxeo's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Onxeo's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 188.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Onxeo Company Filings, last reported 6 months ago.

OTCPK:OXNX.F Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 42.25 0.10 11.01
2018-03-31 42.25 0.10 11.01
2017-12-31 49.87 0.13 14.28
2017-09-30 49.87 0.13 14.28
2017-06-30 96.81 0.16 27.65
2017-03-31 96.81 0.16 27.65
2016-12-31 94.09 0.11 29.24
2016-09-30 94.09 0.11 29.24
2016-06-30 94.21 0.07 19.60
2016-03-31 94.21 0.07 19.60
2015-12-31 102.80 0.07 33.79
2015-09-30 102.80 0.07 33.79
2015-06-30 110.69 1.78 42.92
2015-03-31 110.69 1.78 42.92
2014-12-31 121.97 1.63 57.23
2014-09-30 121.97 1.63 57.23
2014-06-30 78.45 0.11 19.07
2014-03-31 78.45 0.11 19.07
2013-12-31 7.89 0.09 11.33
2013-09-30 7.44 0.09 11.33
2013-06-30 6.54 0.11 11.92
2013-03-31 6.54 0.11 11.92
2012-12-31 11.74 0.06 14.50
2012-09-30 11.74 0.06 14.50
2012-06-30 15.17 2.31 20.39
2012-03-31 15.17 2.31 20.39
  • Onxeo's level of debt (0.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (1.7% vs 0.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Onxeo has less than a year of cash runway based on current free cash flow.
  • Onxeo has less than a year of cash runway if free cash flow continues to reduce at historical rates of -5% each year.
X
Financial health checks
We assess Onxeo's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Onxeo has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Onxeo's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Onxeo dividends. Estimated to be 0% next year.
If you bought $2,000 of Onxeo shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Onxeo's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Onxeo's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:OXNX.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 2.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1986 Stocks 2.7%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.9%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:OXNX.F Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Onxeo has not reported any payouts.
  • Unable to verify if Onxeo's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Onxeo's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Onxeo has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Onxeo's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Onxeo's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Onxeo afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Onxeo has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Onxeo's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Judith Greciet
COMPENSATION €646,861
AGE 50
TENURE AS CEO 7.6 years
CEO Bio

Ms. Judith Greciet, Ph.D., Pharmacy, has been the Chief Executive Officer of Onxeo SA (alternate name BioAlliance Pharma) since June 29, 2011. Ms. Greciet served as the Chief Operations Officer - Operations and R&D at Onxeo SA since March 1, 2011. Ms. Greciet served as Deputy Chief Operating Officer of BioAlliance Pharma since March 2011. Ms. Greciet has an exemplary career in the pharmaceutical industry and international groups. Ms. Greciet joined Eisai France in June 2007 after successful achievements at Wyeth Pharmaceuticals France (today Pfizer), LFB Group (Laboratoire Francais du fractionnement et des Biotechnologies, a French bio-pharmaceutical company), Zeneca and Pharmacia, where she held increasing operational and strategic positions involving a managerial scope. She particularly focused on optimizing links with all health actors (researchers, academic practitioners, medical doctors, patient associations, health authorities.). She exercised her talents in the oncology and immunology areas with innovative products such as Enbrel (in rheumatology). She has served successively as Head of the Oncology Department and of the Hospital Department where she was notably in charge of hospital antibiotherapy projects. She has been a Director of Onxeo SA since June 29, 2011. She holds a Doctorate of Pharmacy in addition to being a graduate of 3(rd) cycle management and pharmaceutical marketing.

CEO Compensation
  • Judith's compensation has increased whilst company is loss making.
  • Judith's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Onxeo management team in years:

3.4
Average Tenure
50
Average Age
  • The tenure for the Onxeo management team is about average.
Management Team

Judith Greciet

TITLE
CEO & Director
COMPENSATION
€647K
AGE
50
TENURE
7.6 yrs

Nicolas Fellmann

TITLE
Chief Financial Officer
AGE
50
TENURE
12.2 yrs

Françoise Bono

TITLE
Chief Scientific Officer
TENURE
1.8 yrs

Audrey Legentil-Dumery

TITLE
Director of Human Resources
TENURE
3.9 yrs

Michel Forest

TITLE
Chief Pharmacist & Quality Assurance Director

Philippe Maitre

TITLE
Chief of US Operations and Executive Vice President
AGE
61
TENURE
2.8 yrs

Olivier de Beaumont

TITLE
Chief Medical Officer
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the Onxeo board of directors in years:

2.9
Average Tenure
59
Average Age
  • The average tenure for the Onxeo board of directors is less than 3 years, this suggests a new board.
Board of Directors

Joe Zakrzewski

TITLE
Chairman
COMPENSATION
€74K
AGE
56
TENURE
3 yrs

Judith Greciet

TITLE
CEO & Director
COMPENSATION
€647K
AGE
50
TENURE
7.6 yrs

Thomas Hofstaetter

TITLE
Independent Director
COMPENSATION
€26K
AGE
70
TENURE
6.7 yrs

Danièle Guyot-Caparros

TITLE
Senior Independent Director
COMPENSATION
€24K
AGE
60
TENURE
3 yrs

Tomas Lindahl

TITLE
Chairman of Scientific Advisory Board
TENURE
1.2 yrs

Nicolas Trebouta

TITLE
Representative Director
AGE
55
TENURE
7.6 yrs

Jean-Pierre Kinet

TITLE
Independent Director
COMPENSATION
€19K
AGE
65
TENURE
2.8 yrs

Jean-Pierre Bizzari

TITLE
Independent Director
COMPENSATION
€21K
AGE
64
TENURE
2.8 yrs

Christine Garnier

TITLE
Independent Director
COMPENSATION
€17K
AGE
57
TENURE
1.8 yrs

Elvira Urgoiti

TITLE
Independent Director
COMPENSATION
€18K
AGE
59
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Onxeo's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Onxeo has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops Beleodaq for the treatment of others liquid or solid tumors; AsiDNA, which is in Phase I clinical trial for the treatment of metastatic melanoma; Livatag that is in Phase III clinical trial to treat advanced primary liver cancer; and Validive, which is in Phase II clinical trial for the treatment of serious mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; and a license agreement with Monopar Therapeutics Inc. to develop Validive. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is based in Paris, France.

Details
Name: Onxeo SA
OXNX.F
Exchange: OTCPK
Founded: 1997
€57,790,127
50,814,757
Website: http://www.onxeo.com
Address: Onxeo SA
49, Boulevard du général Martial Valin,
Paris,
Ile-de-France, 75015,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ONXEO Ordinary Shares Euronext Paris FR EUR 08. Dec 2005
OTCPK OXNX.F Ordinary Shares Pink Sheets LLC US USD 08. Dec 2005
DB C4X Ordinary Shares Deutsche Boerse AG DE EUR 08. Dec 2005
LSE 0NWK Ordinary Shares London Stock Exchange GB EUR 08. Dec 2005
CPSE ONXEO Ordinary Shares OMX Nordic Exchange Copenhagen DK DKK 08. Dec 2005
BATS-CHIXE ONXEOP Ordinary Shares BATS 'Chi-X Europe' GB EUR 08. Dec 2005
Number of employees
Current staff
Staff numbers
37
Onxeo employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/09 01:21
End of day share price update: 2018/10/12 00:00
Last estimates confirmation: 2018/11/29
Last earnings filing: 2018/08/03
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.